Mobilized Leukopaks for Research: High-Yield Starting Material for Advanced Cell Therapy
Mobilized leukopaks are transforming how scientists source high-quality cellular starting material for immunotherapy, regenerative medicine, and translational research.
At CGT Global, our mobilized leukopaks deliver superior CD34+ stem and progenitor cell yields, collected under IRB-approved protocols using clinically validated G-CSF or plerixafor mobilization regimens.
Whether your focus is CAR T development, NK cell expansion, or stem cell isolation, mobilized leukopaks provide the high-volume, high-viability platform your research depends on.
Coming Soon
Why Choose CGT Global Mobilized Leukopaks?
Extensive, Well-Characterized Mobilized Donor Network
Access G-CSF and plerixafor-mobilized donors screened under IRB-approved protocols. Each donor profile includes deep demographic, phenotypic, and HLA data, along with mobilization regimen details and cell yield history.
Whether you’re scaling CAR T, NK, or stem cell programs, our mobilized donor pool ensures you receive high-yield, reproducible starting material with complete transparency.
Donor Recallability
When reproducibility is essential, we make it possible to re-collect mobilized material from the same donor.
This allows your team to perform batch-to-batch validation, assess mobilization response consistency, and standardize your production workflow — minimizing biological variability in translational studies.
Three FDA-Registered, CLIA-Certified Facilities
Our bi-coastal collection network supports mobilized leukapheresis at FDA-registered, CLIA-certified sites near major biotech and cell therapy hubs.
This infrastructure enables rapid scheduling, shorter donor prep times, and localized fulfillment for time-sensitive mobilized collections.
Same-Day Collection & Shipping
Mobilized leukopaks are collected and shipped the same day, preserving peak viability and CD34+ integrity.
Our logistics protocols maintain temperature control and chain-of-custody compliance from donor to lab, ensuring your mobilized starting material arrives fresh, verified, and ready for isolation.
Integrated Supply Chain
CGT Global oversees every stage of mobilized collection — from donor recruitment through G-CSF/plerixafor administration to final delivery.
By eliminating third-party dependencies, we maintain full visibility and quality control, shorten lead times, and remove uncertainty from the supply chain.
Dedicated Client Service Associate Support
Each mobilized project is managed by a dedicated Client Scientific Associate (CSA) who coordinates donor scheduling, documentation, and shipping.
Your CSA provides real-time updates throughout mobilization, collection, and shipment, ensuring your material is delivered on time, compliant, and exactly as specified.
Why Choose CGT Global Leukopaks?
One of the Largest, Most Characterized Mobilized Donor Networks
Access G-CSF and plerixafor-mobilized donors screened under IRB-approved protocols. Each donor profile includes deep demographic, phenotypic, and HLA data, along with mobilization regimen details and cell yield history.
Whether you’re scaling CAR T, NK, or stem cell programs, our mobilized donor pool ensures you receive high-yield, reproducible starting material with complete transparency.
Donor Recallability
When reproducibility is essential, we make it possible to re-collect mobilized material from the same donor.
This allows your team to perform batch-to-batch validation, assess mobilization response consistency, and standardize your production workflow — minimizing biological variability in translational studies.
Same-Day Collection & Shipping
Mobilized leukopaks are collected and shipped the same day, preserving peak viability and CD34+ integrity.
Our logistics protocols maintain temperature control and chain-of-custody compliance from donor to lab, ensuring your mobilized starting material arrives fresh, verified, and ready for isolation.
Three FDA-Registered, CLIA-Certified Facilities
Our bi-coastal collection network supports mobilized leukapheresis at FDA-registered, CLIA-certified sites near major biotech and cell therapy hubs.
This infrastructure enables rapid scheduling, shorter donor prep times, and localized fulfillment for time-sensitive mobilized collections.
Integrated Supply Chain
CGT Global oversees every stage of mobilized collection — from donor recruitment through G-CSF/plerixafor administration to final delivery.
By eliminating third-party dependencies, we maintain full visibility and quality control, shorten lead times, and remove uncertainty from the supply chain.
Dedicated Client Service Associate Support
Each mobilized project is managed by a dedicated Client Scientific Associate (CSA) who coordinates donor scheduling, documentation, and shipping.
Your CSA provides real-time updates throughout mobilization, collection, and shipment, ensuring your material is delivered on time, compliant, and exactly as specified.
What Are Mobilized Leukopaks?
Mobilized leukopaks are specialized peripheral blood collections obtained through apheresis after healthy donors receive pharmacologic agents such as granulocyte-colony stimulating factor (G-CSF) or plerixafor (Mozobil®).
This controlled process, known as stem cell mobilization, stimulates the bone marrow to release hematopoietic stem and progenitor cells (HSPCs) into circulation. The result is a higher concentration of CD34+ stem cells and total nucleated cells (TNCs) compared to standard, non-mobilized leukopaks.
Mobilized leukopaks deliver significant performance advantages:
-
Up to 10× greater CD34+ cell yield
-
More consistent donor profiles and reproducible lots
-
Fewer isolations to reach target cell counts
-
Superior viability after shipping or cryopreservation
Mobilization is performed under IRB-approved, medically supervised protocols to ensure donor safety and consistent outcomes.
Donors may receive G-CSF over several days, plerixafor as a rapid single-dose regimen, or a combination mobilization program for maximal yield.
Collections are scheduled at peak mobilization and processed immediately to preserve cellular integrity and function.
Because of their high CD34+ and immune cell content, mobilized leukopaks are the preferred starting material for cell and gene therapy, including CAR T-cell manufacturing, NK-cell expansion, gene editing, and regenerative medicine research.
By combining enhanced yields with reproducible performance, CGT Global Mobilized Leukopaks enable scientists to scale advanced cell-based therapies with confidence.
Mobilization Methods
G-CSF Mobilization
G-CSF (filgrastim) is the most established mobilizing agent used to expand HSPCs and myeloid lineage cells.
Donors typically receive subcutaneous G-CSF injections for 4–5 days prior to collection.
Advantages:
-
Proven and well-tolerated
-
Produces high CD34+ and monocyte counts
-
Suitable for CAR T, NK, and DC vaccine research
Typical timeline:
-
Day 1–4: Daily G-CSF injections (dose based on body weight)
-
Day 5: Leukapheresis performed at peak mobilization
-
Post-collection: Mild, temporary side effects (bone ache, fatigue) typically resolve within 24–48 hours
Plerixafor Mobilization
Plerixafor (AMD3100, Mozobil®) blocks CXCR4 binding in bone marrow niches, rapidly releasing HSPCs into circulation.
It’s often used alone or combined with G-CSF.
Advantages:
-
Faster mobilization (within 24 hours)
-
Enriches for multipotent progenitors
-
Ideal for short-notice research timelines
Typical timeline:
-
Day 1: Single subcutaneous dose of plerixafor
-
8–12 hours later: Leukapheresis collection performed
-
Can be used alone or added to G-CSF to boost yields
Combination Mobilization (G-CSF + Plerixafor)
Combining both agents offers synergistic effects, producing the highest possible CD34+ yields and optimal leukocyte distribution.
This hybrid approach is preferred for high-demand applications requiring maximum recovery.
Typical timeline:
-
Days 1–4: Daily G-CSF injections
-
Day 5 (morning): Plerixafor injection
-
Day 5 (evening): Apheresis performed at peak circulating stem cell count
Benefits:
-
Highest achievable CD34+ and TNC levels
-
Reduced donor-to-donor variability
-
Often used for high-demand cell therapy programs
Cryopreserved Mobilized Leukopaks
Cryopreserved units provide long-term availability for planned experiments or batch standardization.
Advantages:
-
Long shelf life
-
Consistent COA metrics
-
Convenient for repeat studies or multi-site programs
Applications of Mobilized Leukopaks
Mobilized leukopaks serve as premium source material for:
-
CAR T and TCR T cell development
-
NK cell expansion and functional assays
-
CD34+ stem/progenitor isolation
-
Dendritic cell vaccine research
-
Gene editing, CRISPR, and reprogramming studies
-
Assay standardization and QC benchmarking
These collections are particularly useful when your downstream process depends on cell purity, reproducibility, and scalability.
CGT Global Mobilized Leukopak Specifications
| Parameter | Typical Range / Specification |
|---|---|
| Mobilization Method | G-CSF, Plerixafor, or Combination |
| Cell Count (TNC) | 10–20 Billion per bag |
| CD34+ Content | ≥ 1–2 × 10⁸ cells |
| Viability (Fresh) | ≥ 95 % |
| Viability (Cryo) | ≥ 90 % post-thaw |
| Collection Volume | ~ 250–350 mL |
| Donor Screening | IRB-approved, FDA-compliant infectious disease testing |
| Formats | Fresh or Cryopreserved |
| COA Included | Cell counts, viability, mobilization agent, donor metadata |
| Customization Options | HLA typing, CMV status, BMI range, sex, ethnicity |
Every mobilized leukopak includes a Certificate of Analysis (COA) confirming TNC, CD34+, viability, and mobilization details. Optional donor matching or phenotype requests are supported through CGT Global’s donor network.
Testimonials
"The CGT Global CSA team is outstanding, they know our project inside and out and proactively handle every detail. From our first inquiry to delivery, they made the process seamless. It’s rare to work with a team that combines scientific expertise with genuine human support."
— Dr. Karen M., Immunotherapy Research Scientist
"We rely on CGT Global leukopaks because the quality is always consistent. Every batch meets our strict experimental standards, and the viability and cell counts are exactly as promised. That level of reproducibility is critical for our preclinical work."
— Dr. Alex P., Senior Cell Therapy Researcher
"CGT Global delivers on time, every time. Same-day collections and next-day shipments mean our experiments never have to wait. Their attention to logistics and scheduling makes them a true partner in our research."
— Dr. Priya S., Biotech Project Manager
"We’ve been sourcing leukopaks from CGT Global for several years. Their facilities, donor pool, and scientific support are unmatched. But what really sets them apart is the team — they understand both the science and the practical needs of researchers, making every order effortless."
— Dr. Michael L., Translational Medicine Lead
Our Facilities
Our CLIA-certified clinical processing lab delivers FDA clinical-grade leukopaks with uncompromising quality — backed by validated protocols, advanced cryopreservation, mobilization, and custom cell enrichment.
Feeding into the lab are CGT Global’s FDA-registered collection clinics in Boston, Philadelphia, and Folsom, equipped with Spectra Optia® systems and staffed by expert nurses and scientists. Supporting these sites is our Reno facility, home to 50,000 sq. ft. of state-of-the-art cryogenic storage capacity. With strategic locations, we offer same-day delivery to major biotech hubs and next-day delivery nationwide, sourcing from a diverse, recallable donor pool to meet your exact study needs.
Boston, MA – Advanced Collection Hub in the Heart of Biotech
Located minutes from the world’s leading research institutions, our Boston facility is FDA-registered and CLIA-certified, equipped with state-of-the-art apheresis technology, and staffed by experienced nurses and scientists. Its proximity to the Greater Boston biotech corridor enables same-day delivery to local labs and rapid turnaround for East Coast clients.
Philadelphia, PA – Scalable Clinical & Research Collections
Our Philadelphia site serves as a high-capacity hub for both GMP and research-grade collections. FDA-registered and CLIA-certified, this location is optimized for large-scale donor programs, mobilized collections, and complex custom processing. Centrally positioned, it offers next-day delivery to most U.S. destinations and efficient global shipping connections.
Folsom, CA – West Coast Speed with National Reach
Strategically located to serve West Coast biotech hubs, our Folsom facility delivers fresh collections to California-based researchers the same day, with rapid shipping across the Pacific and to the rest of the U.S. Fully FDA-registered and CLIA-certified, it offers the same stringent quality standards and customizable donor options as our East Coast sites.
Reno, NV – Cryo-Facilities in Strategic Locations
Located in a major transportation and logistics hub, our Reno headquarters offers a 50,000 sq ft freezer with a -80 degree space.
Deep Donor Characterization
Our donor database includes:
-
Demographics and medical history
-
Disease characterization and outcome data
-
CBC reports, vaccination status, and viral-negative screening
-
Immunophenotyping via flow cytometry
-
HLA-typing and recallable donors
All donors are initially screened before their first donation and rescreened every 3 months to maintain our strict standards.
Custom Processing & Assays
In addition to leukopak collection, our in-house labs can provide:
-
PBMC isolation
-
BMMCs, DTCs, enriched cell populations
-
T-cell expansion
-
Immunophenotyping panels
-
Purity assessments
-
ELISA, ELISpot, Fluorospot assays
-
Custom assay development
Select donors by demographic or disease state, specify processing and isolation methods, and request packaging that fits your lab workflow. Every leukopak is made to match your study design, not the other way around.
